IP
QNCX icon

Intellectus Partners’s Quince Therapeutics QNCX Stock Holding History

Intellectus Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-267
Closed -$5.41K – 326
2026
Q1 		$5.41K Hold
267
– – ﹤0.01% 287
2025
Q4 		$179K Buy
+267
New +$134K 0.03% 277
2025
Q3 		– Sell
-267
Closed -$88K – 291
2025
Q2 		$88K Hold
267
– – 0.02% 270
2025
Q1 		$70.9K Buy
+267
New +$81.5K 0.02% 262
2024
Q4 		– Sell
-268
Closed -$41.5K – 284
2024
Q3 		$41.5K Buy
268
+1
+0.4% +$143 0.01% 258
2024
Q2 		$40K Sell
267
-2
-0.7% -$361 0.01% 254
2024
Q1 		$57K Buy
269
+1
+0.4% +$248 0.02% 256
2023
Q4 		$56.2K Hold
268
– – 0.02% 241
2023
Q3 		$60K Hold
268
– – 0.02% 254
2023
Q2 		$80.6K Buy
+268
New +$83.4K 0.02% 256
2022
Q1 		– Sell
-166
Closed -$419K – 259
2021
Q4 		$419K Sell
166
-48
-22% -$293K 0.11% 191
2021
Q3 		$3.93M Buy
214
+47
+28% +$747K 0.95% 17
2021
Q2 		$1.77M Buy
167
+57
+52% +$478K 0.4% 62
2021
Q1 		$794K Buy
110
+40
+57% +$288K 0.22% 136
2020
Q4 		$388K Buy
70
+43
+159% +$381K 0.12% 178
2020
Q3 		$265K Buy
27
+1
+4% +$9.1K 0.1% 182
2020
Q2 		$241K Buy
+26
New +$238K 0.09% 190

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Intellectus Partners's QNCX Position: Q2 2026 in Review

Intellectus Partners sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 267 shares — an estimated $5.41K sold.

Intellectus Partners first reported a position in QNCX in Q2 2020 and held it in 17 quarters. The position peaked at $3.93M in Q3 2021. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Intellectus Partners reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Intellectus Partners sold 267 Quince Therapeutics shares in Q2 2026, an estimated $5.41K.
  • Intellectus Partners first reported a position in Quince Therapeutics in Q2 2020 and held it in 17 quarters.
  • Intellectus Partners's Quince Therapeutics position peaked at $3.93M in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.